

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Albania	Guyana	Panama
Algeria	Haiti	Peru
Argentina	Honduras	Qatar
Armenia	Hong Kong	Republic of Korea
Aruba	Israel	Saudi Arabia
Australia	Jamaica	Serbia
Azerbaijan	Japan	Singapore
Bahrain	Jordan	South Africa
Bosnia and Herzegovina	Kazakhstan	Switzerland
Botswana	Kenya	Taiwan
Brazil	Kuwait	Thailand
Canada	Kyrgyzstan	Trinidad and Tobago
Chile	Lebanon	Turkey
China	Macau	Uganda
Colombia	Macedonia	Ukraine
Costa Rica	Mexico	United Arab Emirates
Curacao	Moldova	United Kingdom
Dominican Republic	Mongolia	United States of America
Ecuador	Morocco	Uruguay
El Salvador	Namibia	Uzbekistan
European Union	New Zealand	
Georgia	Nigeria	
Ghana	Oman	
Guatemala	Pakistan	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 07 September 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.